CTLA-4 and PD-1 blocking agents affects longitudinal and radial strain in preclinical models, increases systemic SDF-1, cardiac fibronectin, S-100 calgranulin, galectine-3 and NLRP-3/MyD-88 pathways
Nicola Maurea(Cancer Institute (WIA)), Vincenzo Quagliariello(Cancer Institute (WIA)), Giuseppe Palma(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Margherita Passariello(Federico II University Hospital), Ciro Cipullo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Andrea Paccone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Claudia De Lorenzo(Istituto Nazionale di Fisica Nucleare, Sezione di Napoli), I Bisceglia(Carlo Forlanini Hospital), Martina Iovine(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Francesca Bruzzese(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Annabella Di Mauro(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Maria Laura Canale(Ospedale Versilia), Antonio Luciano(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")
Cited by 1
Related Papers
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer
|Journal of Cardiac Failure|2011|116
Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience
|Cancer Biology & Therapy|2010|108
Resveratrol in Cancer Patients: From Bench to Bedside
|International Journal of Molecular Sciences|2020|105
Ranolazine Protects from Doxorubicin-Induced Oxidative Stress and Cardiac Dysfunction
|European Journal of Heart Failure|2014|92